Citations

Showing 10 of 108094 citations.

High temporal resolution gastric emptying breath tests in mice
Miller, Katie E., Bajzer, Ž., Hein, Stephanie, Phillips, Jessica E., Syed, Sabriya A. , Wright, Alec M., Cipriani, Gianluca , Szurszewski, Joseph H., Farrugia, Gianrico , Ordog, T., Linden, D R , Gibbons, Simon J. , Ordog, T., Linden, David R.

Mayo Clinic

Neurogastroenterology & Motility | March 25, 2018 | Volume: 30 | Issue: 8 | Pages: No page available

10.1111/nmo.13333 | PMID 29575442 Get It

Abstract Background Gastric emptying is a complex physiological process regulating the division of a meal into smaller partitions for the small intestine. Disrupted gastric emptying contributes to digestive disease, yet current measures may not reflect different mechanisms by which the process can be altered. Methods We have developed high temporal resolution solid and liquid gastric emptying breath tests in mice using [ 13 C]‐octanoic acid and off axis‐ integrated cavity output spectroscopy ( OA ‐ ICOS ). Stretched gamma variate and 2‐component stretched gamma variate models fit measured breath excretion data. Key Results These assays detect acceleration and delay using pharmacological (7.5 mg/kg atropine) or physiological (nutrients, cold exposure stress, diabetes) manipulations and remain stable over time. High temporal resolution resolved complex excretion curves with 2 components, which was more prevalent in mice with delayed gastric emptying following streptozotocin‐induced diabetes. There were differences in the gastric emptying of Balb/c vs C57Bl6 mice, with slower gastric emptying and a greater occurrence of two‐phase gastric emptying curves in the latter strain. Gastric emptying of C57Bl6 could be accelerated by halving the meal size, but with no effect on the occurrence of two‐phase gastric emptying curves. A greater proportion of two‐phase gastric emptying was induced in Balb/c mice with the administration of PYY (8‐80 nmol) 60 min following meal ingestion. Conclusions and Inferences Collectively, these results demonstrate the utility of high temporal resolution gastric emptying assays. Two‐phase gastric emptying is more prevalent than previously reported, likely involves intestinal feedback, but contributes little to the overall rate of gastric emptying.
Recurrent GNA 14 mutations in anastomosing haemangiomas
Bean, Gregory R. , Joseph, Nancy M. , Folpe, Andrew L. , Horvai, Andrew , Umetsu, Sarah E.

Mayo Clinic

Histopathology | March 25, 2018 | Volume: 73 | Issue: 2 | Pages: 354-357

10.1111/his.13519 | PMID 29574926 Get It

Metastatic renal cell carcinoma presenting with melena
Sadhale, Ashwini, Adike, Abimbola , Lam‐Himlin, Dora

Mayo Clinic

Clinical Case Reports | March 25, 2018 | Volume: 6 | Issue: 5 | Pages: 961-962

10.1002/ccr3.1492 | PMID 29744101 Get It

Key Clinical Message Renal cell carcinoma is a highly malignant neoplasm. Metastasis to the pancreas and gastrointestinal tract is rare. In this case report, we show images of metastatic renal cell carcinoma to the upper gastrointestinal tract in a patient who presented with melena.
Phenotypic Variability of c.436delC DCAF17 Gene Mutation in Woodhouse-Sakati Syndrome
Almeqdadi, Mohammad , Kemppainen, Jennifer L., Pichurin, Pavel N. , Gavrilova, Ralitza H.

Mayo Clinic

American Journal of Case Reports | March 25, 2018 | Volume: 19 | Issue: No issue available | Pages: 347-353

10.12659/ajcr.907395 | PMID 29574468 Get It

A rapid and reliable chromosome analysis method for products of conception using interphase nuclei
Babu, Ramesh , Dyke, Daniel L. Van , Bhattacharya, Saurabh Kumar , Dev, Vaithilingam G., Liu, Mingya, Kwon, Minjae, Gu, Guangyu , Koduru, Prasad , Rao, Nagesh, Williamson, Cynthia M., Fuentes, Sarah, Papa, Stephen, Kopuri, Srikanthi, Lal, Vandana , Van Dyke, Daniel L, Williamson, Cynthia, Fuentes, Ernesto J.

Mayo Clinic

Molecular Genetics & Genomic Medicine | March 24, 2018 | Volume: 6 | Issue: 3 | Pages: 370-381

10.1002/mgg3.381 | PMID 29573570 Get It

AbstractBackgroundKaryotype determination has a central role in the genetic workup of pregnancy loss, as aneuploidy (trisomy and monosomy) and polyploidy (triploidy and tetraploidy) are the cause in at least 50% of first trimester, 25% of second trimester, and 11% of third trimester miscarriages. There are several limitations with the current approaches of obtaining a karyotype using traditional cytogenetics, fluorescence in situ hybridization with a limited number of probes, and chromosomal microarray. These include culture failure, incomplete results, lower sensitivity, and longer reporting time.MethodsTo overcome current limitations, a novel molecular assay is developed with a Standard Resolution Interphase Chromosome Profiling probe set which is a variation of the recently developed High Resolution probe set. It generates a molecular karyotype that can detect all major changes commonly associated with pregnancy loss. Initial familiarization of signal patterns from the probe set was used, followed by validation of the method using 83 samples from miscarriages in a blind study from three different laboratories. Finally, the clinical utility of the method was tested on 291 clinical samples in two commercial reference laboratory settings on two different continents.ResultsThe new molecular approach not only identified all the chromosome changes observed by current methods, but also significantly improved abnormality detection by characterizing derivative chromosomes and finding subtle subtelomeric rearrangements, balanced and unbalanced. All Robertsonian translocations were also detected. The abnormality rate was 54% on clinical samples from commercial laboratory 1 and 63% from laboratory 2.ConclusionThe attributes of this method make it an ideal choice for the genetic workup of miscarriages, namely (1) near 100% successful results, (2) greater sensitivity than conventional chromosome analysis or FISH panels, (3) rapid reporting time, and (4) favorable comparisons with chromosomal microarray.
Meniscal root tears: a silent epidemic
Cinque, Mark E., Faucett, Scott C. , Krych, Aaron J. , LaPrade, Robert F. , Krych, Aaron J , Chahla, Jorge , Moatshe, Gilbert , LaPrade, Robert F

Mayo Clinic

British Journal of Sports Medicine | March 24, 2018 | Volume: 52 | Issue: 13 | Pages: 872-876

10.1136/bjsports-2017-098942 | PMID 29574455 Get It

A real‐world observational cohort of patients with primary biliary cholangitis: TARGET‐primary biliary cholangitis study design and rationale
Bowlus, Christopher L. , Carey, Elizabeth J. , Crawford, Julie M. , Deane, Karen, Mayo, Marlyn J. , Kim, W. Ray , Fried, Michael, Bowlus, Christopher L , Carey, Elizabeth, Levy, Cynthia

Mayo Clinic

Hepatology Communications | March 24, 2018 | Volume: 2 | Issue: 5 | Pages: 484-491

10.1002/hep4.1173 | PMID 29761165 Get It

Primary biliary cholangitis (PBC) is a rare chronic cholestatic liver disease that may progress to biliary cirrhosis if left untreated. The first‐line therapy for PBC is ursodeoxycholic acid (UDCA). Unfortunately, 1 of 3 patients does not respond to UDCA. These patients are at risk for developing clinical events, including cirrhosis, complications of portal hypertension, hepatocellular carcinoma, liver transplant, or death. Recently, the U.S. Food and Drug Administration approved obeticholic acid to be used in certain patients with PBC. Off‐label therapies are also used, and several other therapies are currently under evaluation. Real‐world effectiveness of newly approved and off‐label therapies remains unknown. TARGET‐PBC is a 5‐year, longitudinal, observational study of patients with PBC that will evaluate the effectiveness of clinical practice interventions and provide practical information unobtainable in registration trials. Enrollment will take place at both academic and community sites. In addition to consenting to medical records review, participants will be asked to provide an annual blood sample and complete patient reported outcome surveys at predetermined intervals. Any available liver biopsies will be digitally preserved. Conclusion: Key study outcomes will be the evaluation of the safety and effectiveness of PBC interventions and the assessment of disease progression under real‐world conditions. (Hepatology Communications 2018;2:484‐491)
Concurrent Sweet’s syndrome and myopericarditis following mesalamine therapy
Shabtaie, Samuel A. , Tan, Nicholas Y. , Parikh, Riddhi S. , Papadakis, Konstantinos A.

Mayo Clinic

BMJ Case Reports | March 24, 2018 | Volume: 2018 | Issue: No issue available | Pages: bcr-2017-223851

10.1136/bcr-2017-223851 | PMID 29574433 Get It

Mesalamine, or 5-aminosalicylic acid, is a frequently used medication for the treatment of inflammatory bowel disease (IBD). We report the case of a 40-year-old woman recently diagnosed with IBD and started on mesalamine, who presented with new onset tender skin lesions 3 days following medication administration. One day following the onset of skin lesions, the patient developed acute chest pain, shortness of breath, ECG changes, troponemia, C-reactive protein elevation and pericardial enhancement on cardiac MRI consistent with myopericarditis. Subsequent skin biopsy confirmed the diagnosis of Sweet’s syndrome. On cessation of the drug, both the skin lesions and the cardiac symptoms resolved in combination with anti-inflammatory therapy. While mesalamine has been previously associated with myocarditis and pericarditis, to our knowledge this is the first case of coexisting Sweet’s syndrome with myopericarditis in the context of mesalamine therapy.
Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective
Brennan, Alan , Hatswell, Anthony J. , Porter, J. , Sapra, Sandhya, Villa, Guillermo , Shah, Neel , Tepper, Stewart J. , Dodick, David, Lipton, Richard B. , Palmer, Stephen , Dodick, David W.

Mayo Clinic

Journal of Medical Economics | March 24, 2018 | Volume: 21 | Issue: 7 | Pages: 666-675

10.1080/13696998.2018.1457533 | PMID 29571276 Get It

Molecular neuroimaging in primary progressive aphasia with predominant agraphia
Utianski, Rene L. , Savica, Rodolfo , Whitwell, Jennifer L. , Josephs, Keith A. , Utianski, Rene L , Duffy, Joseph R. , Whitwell, Jennifer L. , Machulda, Mary M.

Mayo Clinic

Neurocase | March 23, 2018 | Volume: 24 | Issue: 2 | Pages: 121-123

10.1080/13554794.2018.1454963 | PMID 29569990 Get It